10 studies found for:    SAR236553 | Sanofi [Lead] | Regeneron | Phase 3
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: matching placebo alirocumab SAR236553 (REGN727);   Drug: Ezetimibe;   Other: matching placebo for Ezetimibe
2 Active, not recruiting Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: matching placebo alirocumab SAR236553 (REGN727);   Drug: Ezetimibe;   Drug: matching placebo for Ezetimibe
3 Active, not recruiting Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)
Condition: Hypercholesterolaemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo
4 Active, not recruiting Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
5 Completed Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: Placebo
6 Active, not recruiting Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: alirocumab SAR236553 (REGN727)
7 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
8 Active, not recruiting Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727) Dose Regimen A;   Drug: alirocumab SAR236553 (REGN727) Dose Regimen B;   Drug: alirocumab matching placebo
9 Active, not recruiting Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: alirocumab SAR236553 (REGN727);   Drug: pravastatin;   Drug: simvastatin;   Drug: fluvastatin;   Drug: atorvastatin;   Drug: pitavastatin;   Drug: rosuvastatin
10 Recruiting Open Label Study of Long Term Safety Evaluation of Alirocumab
Condition: Hypercholesterolemia
Intervention: Drug: Alirocumab SAR236553 (REGN727)

Indicates status has not been verified in more than two years